Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments

All NewsSeptember 15, 2025

Monte Rosa’s stock jumps as it partners with Novartis to develop degraders for immune diseases, with up to $5.7 billion in payments.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent